Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Konkret geht es um den Diabetes-Patienten mit kardiovaskulären Erkrankungen oder Risiken, die Herzinsuffizienz sowie die kardiovaskuläre Primär- und Sekundärprävention. Sind Sie hier schon auf dem neuesten Stand? Unsere Experten beleuchten, wo und warum das bisherige Procedere geändert werden soll und was in der Praxis sinnvoll ist. Holen Sie sich Ihr Update und 2 CME-Punkte beim MMW-Webinar am 24. April von 17.30 bis 19 Uhr. 
Erweiterte Suche
Anmelden
nach oben
European Journal of Nuclear Medicine and Molecular Imaging
Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging 2/2018

27.11.2017 | Editorial Commentary

Could 68Ga-somatostatin analogues be an important alternative to 18F-DOPA PET/CT in pediatrics?

verfasst von: Arnoldo Piccardo, Giorgio Treglia

Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging | Ausgabe 2/2018

Einloggen, um Zugang zu erhalten

Excerpt

A growing body of evidence supports the role of fluorine-18 dihydroxyphenylalanine (18F–DOPA) PET/CT in different types of pediatric diseases [1‐4]. Although, this radiotracer remains not largely available, its routine use is increasing in clinical practice, and it should be considered as an important diagnostic option in those Nuclear Medicine Departments highly specialized in pediatrics. The principal limitation of 18F–DOPA is its high cost due to its not efficient production. Indeed, synthesis of 18F–DOPA has generally been realized using an electrophilic approach. However, this electrophilic strategy produces only low amounts (0.6–2.6 GBq) of 18F–DOPA even when using expensive production methods [5, 6]. …
Literatur
1.
Pfluger T, Piccardo A. Neuroblastoma: MIBG imaging and new tracers. Semin Nucl Med. 2017;47:143–57.CrossRefPubMed
2.
Morana G, Piccardo A, Tortora D, Puntoni M, Severino M, Nozza P, et al. Grading and outcome prediction of pediatric diffuse astrocytic tumors with diffusion and arterial spin labeling perfusion MRI in comparison with 18F-DOPA PET. Eur J Nucl Med Mol Imaging. 2017;44:2084–93.CrossRefPubMed
3.
Morana G, Puntoni M, Garrè ML, Massollo M, Lopci E. Naseri M et al ability of (18)F-DOPA PET/CT and fused (18)F-DOPA PET/MRI to assess striatal involvement in paediatric glioma. Eur J Nucl Med Mol Imaging. 2016;43:1664–72.CrossRefPubMed
4.
Lu MY, Liu YL, Chang HH, Jou ST, Yang YL, Lin KH, et al. National Taiwan University Neuroblastoma Study Group. Characterization of neuroblastic tumors using 18F–FDOPA PET. J Nucl Med. 2013;54:42–9.CrossRefPubMed
5.
Lemaire C, Libert L, Franci X, Genon JL, Kuci S, Giacomelli F, et al. Automated production at the curie level of no-carrier-added 6-[(18)F]fluoro-L-dopa and 2-[(18)F]fluoro-L-tyrosine on a FASTlab synthesizer. J Labelled Comp Radiopharm. 2015 15;58:281–290.
6.
Azad BB, Chirakal R, Schrobilgen GJ. Trifluoromethanesulfonic acid, an alternative solvent medium for the direct electrophilic fluorination of DOPA: new syntheses of 6-[18F]fluoro-L-DOPA and 6-[18F]fluoro-D-DOPA. J Labelled Comp Radiopharm. 2007;50:1236–42.CrossRef
7.
Arnoux JB, Verkarre V, Saint-Martin C, Montravers F, Brassier A, Valayannopoulos V, et al. Congenital hyperinsulinism: current trends in diagnosis and therapy. Orphanet J Rare Dis. 2011;6:63.CrossRefPubMedPubMedCentral
8.
Pierro A. Nah SASurgical management of congenital hyperinsulinism of infancy. Semin Pediatr Surg. 2011;20:50–3.CrossRefPubMed
9.
Ribeiro MJ, Boddaert N, Bellanné-Chantelot C, Bourgeois S, Valayannopoulos V, Delzescaux T, et al. The added value of [18F]fluoro-L-DOPA PET in the diagnosis of hyperinsulinism of infancy: a retrospective study involving 49 children. Eur J Nucl Med Mol Imaging. 2007;34:2120–8.CrossRefPubMed
10.
Christiansen CD, Petersen H, Nielsen AL, Detlefsen S, Brusgaard K, Rasmussen L, Melikyan M, Ekström K, Globa E, Rasmussen AH, Hovendal C, Christesen HT. 18F-DOPA PET/CT and 68Ga-DOTANOC PET/CT scans as diagnostic tools in focal congenital hyperinsulinism: a blinded evaluation. Eur J Nucl Med Mol Imaging 2017.
11.
Kumar U, Sasi R, Suresh S, Patel A, Thangaraju M, Metrakos P, et al. Subtype-selective 33 expression of the five somatostatin receptors (hSSTR1-5) in human pancreatic islet cells: a 34 quantitative double-label immunohistochemical analysis. Diabetes. 1999;48:77–85.CrossRefPubMed
12.
Yadav D, Dhingra B, Kumar S, Kumar V, Dutta AK. Persistent hyperinsulinemic hypoglycaemia 36 of infancy. J Pediatr Endocrinol Metab. 2012;25:591–3.CrossRefPubMed
13.
Dutta S, Venkataseshan S, Bal C, Rao KLN, Gupta K, Bhattacharya A, et al. Novel use of somatostatin receptor scintigraphy in localization of focal congenital Hyperinsulinism: promising but fallible. J Pediatr Endocrinol Metab. 2009;22:965–70.PubMed
14.
Treglia G, Mirk P, Giordano A, Rufini V. Diagnostic performance of fluorine-18-dihydroxyphenylalanine positron emission tomography in diagnosing and localizing the focal form of congenital hyperinsulinism: a meta-analysis. Pediatr Radiol. 2012;42:1372–9.CrossRefPubMed
15.
O’Dorisio MS, Chen F, O’Dorisio TM, Wray D, Qualman SJ. Characterization of somatostatin receptors on human neuroblastoma tumors. Cell Growth Differ. 1994;5:1–8.PubMed
16.
Albers AR, O’Dorisio MS, Balster DA, Caprara M, Gosh P, Chen F, et al. Somatostatin receptor gene expression in neuroblastoma. Regul Pept. 2000;88:61–73.CrossRefPubMed
17.
Piccardo A, Lopci E, Conte M, Garaventa A, Foppiani L, Altrinetti V, et al. Comparison of (18)F-dopa PET/CT and (123)I-MIBG scintigraphy in stage 3 and 4 neuroblastoma: a pilot study. Eur J Nucl Med Mol Imaging. 2012;39:57–61.CrossRefPubMed
18.
Kroiss A, Putzer D, Uprimny C, Decristoforo C, Gabriel M, Santner W, et al. Functional imaging in phaeochromocytoma and neuroblastoma with 68Ga-DOTA-Tyr 3-octreotide positron emission tomography and 123I-metaiodobenzylguanidine. Eur J Nucl Med Mol Imaging. 2011;38:865–73.CrossRefPubMed
19.
Gains JE, Bomanji JB, Fersht NL, Sullivan T, D’Souza D, Sullivan KP, et al. 177Lu-DOTATATE molecular radiotherapy for childhood neuroblastoma. J Nucl Med. 2011;52(7):1041–7.CrossRefPubMed
20.
Kong G, Hofman MS, Murray WK, Wilson S, Wood P, Downie P, et al. Initial experience with Gallium-68 DOTA-Octreotate PET/CT and peptide receptor radionuclide therapy for pediatric patients with refractory metastatic neuroblastoma. J Pediatr Hematol Oncol. 2016;38:87–96.CrossRefPubMed
21.
Packer RJ, Vezina G. Management of and prognosis with medulloblastoma: therapy at a crossroads. Arch Neurol. 2008;65:1419–24.CrossRefPubMed
22.
23.
Gururangan S, Hwang E, Herendon JE II, Fuchs H, George T, Coleman RE. [18F] fluorodeoxyglucose-positron emission tomography in patients with medulloblastoma. Neurosurgery. 2004;55:1280–8.CrossRefPubMed
24.
Albert NL, Weller M, Suchorska B, Galldiks N, Soffietti R, Kim MM, et al. Response assessment in neuro-oncology working group and European Association for Neuro-Oncology recommendations for the clinical use of PET imaging in gliomas. Neuro-Oncology. 2016;18:1199–208.CrossRefPubMedPubMedCentral
25.
Cicone F, Clerico A, Minniti G, Paiano M, Carideo L, Scaringi C, et al. (18)F-DOPA Positron Emission Tomography in Medulloblastoma: 2 Case Reports. World Neurosurg. 2016 Sep;93:490.e7–e11.CrossRef
26.
Cervera P, Videau C, Viollet C, Petrucci C, Lacombe J, Winsky-Sommerer R, et al. Comparison of somatostatin receptor expression in human gliomas and medulloblastomas. J Neuroendocrinol. 2002;14(6):458–71.CrossRefPubMed
27.
Müller HL, Frühwald MC, Scheubeck M, Rendl J, Warmuth-Metz M, Sörensen N, et al. A possible role for somatostatin receptor scintigraphy in thediagnosis and follow-up of children with medulloblastoma. J Neuro-Oncol. 1998;38:27–40.CrossRef
28.
Yüksel M, Lutterbey G, Biersack HJ, Elke U, Hasan C, Gao Z, et al. 111In-pentetreotide scintigraphy in medulloblastoma: a comparison with magnetic resonance imaging. Acta Oncol. 2007;46(1):111–7.CrossRefPubMed
29.
Vaidyanathan G, Affleck DJ, Zhao XG, Keir ST, Zalutsky MR. [177Lu]-DOTAO-Tyr3-octreotate: a potential targeted radiotherapeutic for the treatment of medulloblastoma. Curr Radiopharm. 2010;3:29–36.CrossRefPubMedPubMedCentral
Metadaten
Titel
Could 68Ga-somatostatin analogues be an important alternative to 18F-DOPA PET/CT in pediatrics?
verfasst von
Arnoldo Piccardo
Giorgio Treglia
Publikationsdatum
27.11.2017
Verlag
Springer Berlin Heidelberg
Erschienen in
European Journal of Nuclear Medicine and Molecular Imaging / Ausgabe 2/2018
Print ISSN: 1619-7070
Elektronische ISSN: 1619-7089
DOI
https://doi.org/10.1007/s00259-017-3894-y

Weitere Artikel der Ausgabe 2/2018

European Journal of Nuclear Medicine and Molecular Imaging 2/2018 Zur Ausgabe

Original Article

68Ga-PSMA 11 ligand PET imaging in patients with biochemical recurrence after radical prostatectomy – diagnostic performance and impact on therapeutic decision-making

Original Article

Texture analysis of high-resolution dedicated breast 18 F-FDG PET images correlates with immunohistochemical factors and subtype of breast cancer

Correction

Correction to: 18F-NaF PET/CT: EANM procedure guidelines for bone imaging

Original Article

Patterns of bone tracer uptake on SPECT-CT in symptomatic and asymptomatic patients with primary total hip arthroplasty

Original Article

Prediction of disease-free survival by the PET/CT radiomic signature in non-small cell lung cancer patients undergoing surgery

Original Article

18F-DOPA PET/CT and 68Ga-DOTANOC PET/CT scans as diagnostic tools in focal congenital hyperinsulinism: a blinded evaluation